Document is current
Any future updates will be listed below
-
Authors
Finlay, B. Brett
Goldszmid, Romina
Honda, Kenya http://orcid.org/0000-0001-8937-9835
Trinchieri, Giorgio http://orcid.org/0000-0001-5892-7464
Wargo, Jennifer http://orcid.org/0000-0003-3438-7576
Zitvogel, Laurence
- License Information
-
More Information
Article History
Accepted: 11 June 2020
First Online: 13 July 2020
Competing interests
: B.B.F. is a cofounding scientific advisory board member for Vedanta Biosciences. K.H. is a scientific advisory board member of Vedanta Biosciences and 4BIO CAPITAL. J.W. reports compensation and honoraria from Imedex, Dava Oncology, Omniprex, Ilumina, Gilead, PeerView, Physician Education Resource, MedImmune and Bristol-Myers Squibb. J.W. serves as a consultant advisory board member for Roche/Genentech, Novartis, AstraZeneca, GlaxoSmithKline, Bristol-Myers Squibb, Merck, Biothera Pharmaceuticals and Microbiome DX. J.W. also receives research support from GlaxoSmithKline, Roche/Genentech, Bristol-Myers Squibb and Novartis. J.W. is an adviser and has stock options for Ella Therapeutics. L.Z. is a founder of everImmune, a biotechnology company that develops anticancer probiotics and diagnostic tools to define intestinal dysbiosis in cancer. L.Z. also has an active scientific collaboration (research contract) with Kaleido, Innovate Pharma and Bioaster, which are companies involved in the microbiome space. R.G. and G.T. declare no competing interests.
